Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes

ConclusionsShort-term CSII with vildagliptin as add-on therapy may be an optimized treatment for hospitalized patients with T2DM compared with short-term CSII monotherapy.

http://link.springer.com/10.1007/s13300-020-00758-5

Source: Diabetes Therapy - February 3, 2020 Category: Endocrinology Source Type: research